Dataset Information

The Effect of Fish Oil Supplementations on HDL Proteome, Lipidome and Function

ABSTRACT: Seven health subjects took fish oil supplements (1.125 mg DHA and 875 mg EPA) for 30 days.Prior to supplementation, at 30 day of supplementation and after a 30 day washout period patient plasma was collected. From subject plasma HDL was isolated using a two step ultracentrifugation procced. The isolated HDL was then used in cholesterol efflux assay, anti-inflammatory capacity assay, proteomics and lipidomics.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

SUBMITTER: sara rosarios

LAB HEAD: Nathalie Pamir

PROVIDER: PXD041728 | Pride | 2025-05-06

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	FISHOIL_MASTER_SUMMARY.xlsx	Xlsx
	FISHOIL_MASTER_SUMMARY.xml	Xml
	PAMI-735_Human_HDL_165_POST_500ng_PSRtrapHishamcolumn_25cm_90min_20190730_QE-01.msf	Msf
	PAMI-735_Human_HDL_165_POST_500ng_PSRtrapHishamcolumn_25cm_90min_20190730_QE.raw	Raw
	PAMI-735_Human_HDL_165_PRE_500ng_PSRtrapHishamcolumn_25cm_90min_20190730_QE-01.msf	Msf

Items per page:

1 - 5 of 45

Publications

Fish Oil Supplementation Modifies the Proteome, Lipidome, and Function of High-Density Lipoprotein: Findings from a Trial in Young Healthy Adults.

Mueller Paul A PA Bergstrom Paige P Rosario Sara S Heard Melissa M Pamir Nathalie N

The Journal of nutrition 20240117 4

<h4>Background</h4>Fish oil with the ω-3 fatty acids EPA and DHA is an FDA-approved treatment of patients with severe hypertriglyceridemia. Furthermore, EPA is an FDA-approved treatment of patients with high risk of cardiovascular disease (CVD); however, the cardioprotective mechanisms are unclear.<h4>Objectives</h4>We aimed to determine if fish oil supplementation is cardioprotective due to beneficial modifications in HDL particles.<h4>Methods</h4>Seven fish oil naïve subjects without a history ...[more]

PMID: 38237669

Similar Datasets

Project description:Elevated plasma levels of High Density Lipoprotein (HDL) are associated with decreased risk of cardiovascular disease (CVD). The protective role of HDL in atherosclerosis has been attributed primarily to its ability to remove excess cholesterol from lipid-laden macrophages (foam cells) within the arterial walls. However, clinical trials that raise HDL cholesterol levels have failed to show a benefit casting doubts on our basic understanding of HDL function. Atherosclerosis is a chronic inflammatory condition underlying CVD and driven in part by the recognition of metabolic danger signals by innate immune receptors on macrophages. A potential feature that could contribute to HDL’s protective effects in CVD could be HDL's anti-inflammatory nature, such as its ability to reduce endothelial cell activation. However, the molecular mechanisms by which HDL reduces inflammatory macrophage responses remain poorly understood and difficult to separate from its cholesterol depleting activity. Here we show that HDL protects against Toll like receptor (TLR)-induced inflammation both in vivo and in vitro under normocholesteremic conditions by suppressing the transcription of inflammatory cytokines in a manner independent of its ability to remove cellular cholesterol. We identify Activating Transcription Factor 3 (ATF3), a transcriptional repressor of the CREB family of basic leucine zipper transcription factors, as a HDL-inducible regulator of macrophage activation. HDL’s ability to down modulate TLR responses was severely compromised in ATF3-deficient cells demonstrating that ATF3 mediates HDL's anti-inflammatory effects and may explain the broad anti-inflammatory functions of HDL. Bone marrow-derived macrophages (BMDMs) were obtained by culturing bone marrow cells from 6 to 8 week old wildtype C57BL/6 mice in DMEM supplemented with 10% FCS, 10 mg ml-1 Ciprobay-500 and 40 ng ml-1 M-CSF (R & D Systems). BMDMs of wt mice were pretreated for 6 h with HDL (2 mg ml-1 ) then stimulated with CpG (100 nM) for 4 h. Further wild type or Atf3-deficient BMDMs were pretreated with 2 mg ml-1 HDL for 6 h and subsequently stimulated with CpG (100 nM) or P3C (50 ng ml-1) for 4 h. For carotid artery injury approximately 12-week old male WT and Atf3-deficient mice were anesthetized with i.p. injection of 150 mg/kg ketaminehydrochloride (Ketanest, Pharmacia) and 0.1 mg/kg xylazinehydrochloride (Rompun 2%, Bayer). A small incision from the cranial apex of the sternum to just below the mandible was made. After careful preparation of an approximately 6 mm long segment proximal of the bifurcation, the common carotid artery was electrically denuded. A 4 mm long lesion was made by applying two serial 5 second bursts of 2 Watt using 2 mm wide forceps. The skin was then sutured and the mice allowed to recover in individual cages before returning to their littermates. Three hours later the mice received a single 200 ?l i.v. injection of 20 mg/kg HDL or PBS.